- Press Releases
- Notices
Press Releases To List
-
- Jan.25.2021R & D
- U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
-
- Jan.22.2021R & D
- ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
-
- Jan.21.2021R & D
- U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
Notices To List
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
